Expanding the Orphan Franchise: Sanofi’s Next-Gen Nexviazyme Secures Complete Phase III Efficacy to Supplant Myozyme in Infantile-Onset Pompe Disease

Key Development

Global biopharmaceutical innovator Sanofi has officially released positive top-line data from its pivotal Phase III Baby-COMET clinical trial (ClinicalTrials.gov Identifier: NCT04910776). The clinical readout establishes that Nexviazyme® (avalglucosidase alfa), a next-generation enzyme replacement therapy (ERT), successfully met all primary and secondary efficacy endpoints in treatment-naïve pediatric cohorts presenting with infantile-onset Pompe disease (IOPD)—the most aggressive, rapidly progressive, and highly fatal variant of this rare genetic neuromuscular metabolic disorder.

The international, multi-center, open-label, single-arm study evaluated 17 infants aged 12 months and younger administered an intravenous infusion of avalglucosidase alfa at $40\text{ mg/kg}$ every other week. The study conclusively achieved its primary objective: demonstrating a significant proportion of treatment-naïve infants (aged 0 to 6 months at intake) remaining alive and completely free of invasive ventilation support at Week 52 of continuous therapy. Furthermore, the trial met all key secondary parameters, tracking sustained invasive ventilator-free survival through 12 and 18 months of age, alongside profound numeric optimizations in left ventricular mass Z-scores, Alberta Infant Motor Scale (AIMS) readouts, and urinary glucose tetrasaccharide clearance metrics. Sanofi will formally present the comprehensive dataset at the 19th International Congress on Neuromuscular Diseases in Florence, Italy, on July 8, 2026, anchoring a supplemental Biologics License Application (sBLA) for U.S. FDA label expansion slated for H2 2026.

Why It Matters

• Targeting an Acute, Life-Threatening Neuromuscular Care Gap: Pompe disease stems from an inherited deficiency in the lysosomal acid alpha-glucosidase (GAA) enzyme, forcing toxic accumulations of glycogen across systemic muscle tissues. The hyper-aggressive IOPD phenotype manifests within weeks of birth, triggering catastrophic cardiomyopathy, progressive skeletal muscle wasting, and profound respiratory failure that inevitably terminates in death within the first year of life if left untreated.

• Securing the Next-Generation Product Transition Runway: While Nexviazyme secured U.S. FDA authorization in 2021, its current indication is strictly restricted to late-onset Pompe disease (LOPD) in patients aged one year and older. Consequently, the ultra-critical infantile sector in the U.S. has remained bound for two decades to Sanofi’s legacy agent, Myozyme/Lumizyme (alglucosidase alfa), approved in 2006. Validating Baby-COMET enables Sanofi to systematically execute a high-margin cross-portfolio consumer migration.

• Engineering a 15-Fold Amplification in Binding Avidity: Avalglucosidase alfa is chemically engineered to optimize cellular targeting, carrying an approximate 15-fold increase in active mannose-6-phosphate (M6P) residues compared to legacy Myozyme. This structural modification enhances binding to the M6P receptor pathway, maximizing enzyme lysosomal uptake and active glycogen clearance within cardiac and skeletal muscle matrices.

• Demonstrating Premium Safety Indices in Neonatal Cohorts: The Baby-COMET safety matrix confirmed excellent compound tolerability, registering zero treatment-related serious adverse events (SAEs), zero patient discontinuations, and zero clinical mortalities. Infusion-associated reactions (IARs) manifested in 29.4% of patients and remained entirely manageable under standard clinical mitigation protocols.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, Sanofi’s definitive Phase III Baby-COMET victory represents a highly calculated, textbook execution of “Franchise Lock-In & Orphan Asset Moat Defense” across the international specialty care landscape. Sanofi’s rare disease operational division is currently displaying deep revenue polarization: Nexviazyme global revenues surged over 21% last year to reach €790 million, while legacy asset Myozyme contracted by an identical margin down to €519 million. This revenue decay is the direct result of an intentional, proactive patient switching strategy engineered by Sanofi in the European theater, where the novel compound secured broad labels covering both LOPD and IOPD indications in 2022.

However, the high-yield U.S. infantile landscape has stood as an unapproved regulatory fortress for Nexviazyme, forcing specialist clinicians to navigate cautious, off-label administrative protocols. Designing a registrational clinical trial within the IOPD demographic represents a monumental logistical challenge: the patient incidence pool is exceptionally small, and the window of disease progression is measured in days, rendering the integration of a randomized placebo control arm highly unethical. Sanofi’s ability to navigate a single-arm study design using an external historical comparator group—while securing high-purity, statistically valid clinical outputs—marks a major victory in modern Regulatory Strategy.

Mechanistically, resolving the “invasive ventilator-free survival” index at the one-year milestone is the supreme validator required to guarantee U.S. FDA approval. Transitioning an infant to mechanical ventilation signifies irreversible diaphragmatic and intercostal muscle fibrosis and carries catastrophic healthcare utilization costs. By deploying an engineered, high-affinity M6P architecture, Nexviazyme aggressively purges target lysosomal glycogen blocks before structural architecture degradation occurs, manifested by the dramatic reversal of pathogenic left ventricular hypertrophy. Once the FDA formalizes this label extension in late 2026, Sanofi will establish an impenetrable therapeutic monopoly in the U.S., effectively neutralizing impending generic biosimilar attempts targeting the legacy Myozyme compound, while maximizing the patient Long-Term Value (LTV) from the earliest weeks of life.

Market Implications

1. Redefining the Standard of Care in U.S. Infantile Pompe Management: Upon receiving impending federal clearance, Nexviazyme will instantly supplant Myozyme across clinical guidelines as the default, frontline frontline therapeutic recommendation for newly diagnosed infants, accelerating the total phase-out of the legacy asset from Sanofi’s active commercial catalog.

2. Amplifying Sanofi’s Specialty Rare Disease Cash Flow Ingestion: Onboarding the IOPD registry (comprising roughly 15% of the total diagnosed Pompe population but commanding the highest per-capita specialty care cost profiles due to a continuous $40\text{ mg/kg}$ dosing matrix—double the standard LOPD baseline) will position the franchise to securely enter Sanofi’s multi-billion-dollar blockbuster tier by 2027.

3. Establishing Next-Gen Quantitative Design Benchmarks for Orphan Drug R&D: The validation of the Baby-COMET architecture will serve as a definitive blueprint for specialized biotechs developing orphan therapies. Utilizing highly responsive, quantitative secondary biometric endpoints—such as echocardiographic left ventricular mass indices paired with metabolic urinary glucose tetrasaccharide clearance tracking—will solidify as the preferred regulatory methodology to pass single-arm trials enclosing narrow cohorts under 20 subjects.

Structural Parameters: Phase III Baby-COMET Clinical Trial

Source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-30-05-00-00-3319382